|
WO1998005351A1
(en)
*
|
1996-08-08 |
1998-02-12 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
|
DE69831673C5
(de)
*
|
1997-01-07 |
2015-01-22 |
Amylin Pharmaceuticals, Llc |
Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
|
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
|
BRPI0007823A8
(pt)
|
1999-01-14 |
2017-03-21 |
Amylin Pharmaceuticals Inc |
Métodos de supressão do glucagon
|
|
US20030087820A1
(en)
*
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US7022674B2
(en)
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
|
CA2430934C
(en)
|
2000-12-01 |
2011-06-21 |
Takeda Chemical Industries, Ltd. |
A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
|
|
JP5562510B2
(ja)
|
2001-06-28 |
2014-07-30 |
ノヴォ ノルディスク アー／エス |
修飾ｇｌｐ−１の安定な処方剤
|
|
JP2005501058A
(ja)
*
|
2001-07-31 |
2005-01-13 |
ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ |
Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
|
|
RU2353625C2
(ru)
*
|
2001-10-18 |
2009-04-27 |
Бристол-Маерс Сквибб Компани |
Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний
|
|
DE10238931C1
(de)
*
|
2002-08-24 |
2003-07-31 |
Fh Hildesheim Holzminden Goe |
Verfahren und Vorrichtung zur Vorbereitung eines Finger- oder Fußnagels für eine Beschichtung, insbesondere Lackierung
|
|
CA2501677A1
(en)
*
|
2002-10-22 |
2004-05-06 |
Waratah Pharmaceuticals, Inc. |
Treatment of diabetes
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
KR101198346B1
(ko)
|
2003-04-08 |
2012-11-06 |
노보 노르디스크 에이/에스 |
크로마토그래피 고정상의 재생
|
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
|
WO2005000222A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Amylin Pharmaceuticals, Inc. |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
EP1633391B1
(en)
|
2003-06-03 |
2011-10-19 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
CN102940879B
(zh)
|
2003-06-03 |
2017-06-06 |
诺沃挪第克公司 |
稳定化的药物肽组合物
|
|
EP2292253A3
(en)
|
2003-06-03 |
2011-12-14 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
DE10329324A1
(de)
*
|
2003-06-30 |
2005-02-03 |
Toximed Gmbh |
Pharmarzeutischer Schlankmacher
|
|
JP5518282B2
(ja)
*
|
2003-09-01 |
2014-06-11 |
ノヴォ ノルディスク アー／エス |
安定なペプチドの製剤
|
|
PL3300721T5
(pl)
|
2003-11-20 |
2025-11-17 |
Novo Nordisk A/S |
Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania
|
|
WO2005058252A2
(en)
*
|
2003-12-16 |
2005-06-30 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Glp-1 pharmaceutical compositions
|
|
WO2005072045A2
(en)
*
|
2004-01-30 |
2005-08-11 |
Waratah Pharmaceuticals, Inc. |
The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
|
|
DK1745078T3
(da)
*
|
2004-04-23 |
2009-10-26 |
Conjuchem Biotechnologies Inc |
Fremgangsmåde til oprensning af albuminkonjugater
|
|
WO2005117584A2
(en)
*
|
2004-05-28 |
2005-12-15 |
Amylin Pharmaceuticals, Inc |
Improved transmucosal delivery of peptides and proteins
|
|
EP1789434B1
(en)
|
2004-08-31 |
2013-11-20 |
Novo Nordisk A/S |
Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
|
|
ES2735533T3
(es)
|
2004-11-12 |
2019-12-19 |
Novo Nordisk As |
Formulaciones estables de GLP-1
|
|
EP1841448A2
(en)
*
|
2004-12-30 |
2007-10-10 |
Diakine Therapeutics, Inc. |
Pharmaceutical compositions and methods for restoring beta-cell mass and function
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
US20090227493A1
(en)
*
|
2005-05-27 |
2009-09-10 |
Daiichi Sankyo Company, Limited |
Combined drug for treating diabetes
|
|
PL2347762T3
(pl)
|
2005-08-19 |
2019-09-30 |
Amylin Pharmaceuticals, Llc |
Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
|
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
|
RU2426530C2
(ru)
|
2005-12-22 |
2011-08-20 |
Такеда Фармасьютикал Компани Лимитед |
Твердый препарат
|
|
CN101384623B
(zh)
*
|
2005-12-22 |
2013-07-24 |
常山凯捷健生物药物研发（河北）有限公司 |
白蛋白与治疗剂的预成型偶联物的制备方法
|
|
BRPI0712559A2
(pt)
*
|
2006-05-26 |
2012-11-20 |
Amylin Pharmaceuticals Inc |
composiÇÕes e mÉtodos para o tratamento de insuficiÊncia cardÍaca congestiva
|
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
|
EP2359808B1
(en)
|
2006-08-09 |
2013-05-22 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
|
MX2009001763A
(es)
*
|
2006-08-17 |
2009-02-25 |
Wellstat Therapeutics Corp |
Tratamiento combinado para trastornos metabolicos.
|
|
CN102827284B
(zh)
*
|
2006-11-14 |
2015-07-29 |
上海仁会生物制药股份有限公司 |
带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
|
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
|
KR100805208B1
(ko)
|
2007-03-27 |
2008-02-21 |
주식회사 펩트론 |
엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
|
|
CN104000779A
(zh)
|
2007-04-23 |
2014-08-27 |
精达制药公司 |
促胰岛素释放肽的混悬制剂及其应用
|
|
JP5496082B2
(ja)
*
|
2007-04-30 |
2014-05-21 |
ノボ・ノルデイスク・エー／エス |
タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
|
|
CN101366692A
(zh)
*
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
CN101444618B
(zh)
*
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
CN102026666B
(zh)
*
|
2007-12-11 |
2013-10-16 |
常山凯捷健生物药物研发（河北）有限公司 |
促胰岛素肽缀合物制剂
|
|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
EP2280993A1
(en)
|
2008-05-15 |
2011-02-09 |
Novo Nordisk A/S |
Purification of peptides prepared by solid phase synthesis
|
|
US20110263496A1
(en)
|
2008-05-21 |
2011-10-27 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholesterol and triglycerides
|
|
MX2011001734A
(es)
*
|
2008-08-14 |
2011-06-20 |
Nestec Sa |
Composiciones y metodos para influenciar la saciedad, metabolismo de lipidos y utilizacion de grasas.
|
|
LT2349324T
(lt)
|
2008-10-17 |
2017-12-27 |
Sanofi-Aventis Deutschland Gmbh |
Insulino ir glp-1 agonisto derinys
|
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
|
WO2010138671A1
(en)
|
2009-05-28 |
2010-12-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
|
CN101642562A
(zh)
*
|
2009-08-28 |
2010-02-10 |
江苏万邦生化医药股份有限公司 |
艾塞那肽药用制剂及注射液的制备方法
|
|
NO2462246T3
(enExample)
|
2009-09-28 |
2018-02-03 |
|
|
|
JP5832439B2
(ja)
|
2009-11-13 |
2015-12-16 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
|
|
CN102711804B
(zh)
|
2009-11-13 |
2015-09-16 |
赛诺菲-安万特德国有限公司 |
包含glp-1激动剂和甲硫氨酸的药物组合物
|
|
EP2504019A2
(en)
|
2009-11-25 |
2012-10-03 |
ArisGen SA |
Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
|
|
CN102100912B
(zh)
*
|
2009-12-16 |
2015-04-22 |
上海蓝心医药科技有限公司 |
一种给药组合物及其制备和使用方法
|
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
|
WO2011134471A1
(en)
|
2010-04-27 |
2011-11-03 |
Zealand Pharma A/S |
Peptide conjugates of glp-1 receptor agonists and gastrin and their use
|
|
NZ603399A
(en)
*
|
2010-05-17 |
2014-09-26 |
Cebix Inc |
Pegylated c-peptide
|
|
CN103179978A
(zh)
|
2010-08-30 |
2013-06-26 |
赛诺菲-安万特德国有限公司 |
Ave0010用于制造供治疗2型糖尿病用的药物的用途
|
|
CN102397558B
(zh)
*
|
2010-09-09 |
2013-08-14 |
中国人民解放军军事医学科学院毒物药物研究所 |
Exendin-4类似物的定位聚乙二醇化修饰物及其用途
|
|
EP2438930A1
(en)
*
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
ES2563091T3
(es)
|
2010-09-28 |
2016-03-10 |
Amylin Pharmaceuticals, Llc |
Polipéptidos modificados genéticamente que tienen duración de acción potenciada
|
|
WO2012088157A2
(en)
|
2010-12-22 |
2012-06-28 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonists for islet cell transplantation
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CN102100906A
(zh)
*
|
2011-02-18 |
2011-06-22 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的药用制剂及其制备方法
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
US20140221282A1
(en)
|
2011-05-25 |
2014-08-07 |
Astrazeneca Pharmaceuticals Lp |
Long duration dual hormone conjugates
|
|
EP2526971A1
(en)
|
2011-05-25 |
2012-11-28 |
ArisGen SA |
Mucosal delivery of drugs
|
|
DK2713722T3
(en)
|
2011-05-31 |
2017-07-03 |
Celgene Int Ii Sarl |
Newly known GLP-1 receptor stabilizers and modulators
|
|
JP6006309B2
(ja)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
|
WO2013030160A1
(en)
|
2011-08-29 |
2013-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
CN104144704B
(zh)
|
2011-11-03 |
2018-03-23 |
西兰制药公司 |
Glp‑1受体激动剂肽胃泌素缀合物
|
|
CN104220086A
(zh)
|
2011-11-17 |
2014-12-17 |
塞比克斯股份公司 |
Peg化的c-肽
|
|
HK1202119A1
(en)
|
2011-12-12 |
2015-09-18 |
Celgene International Ii Sàrl |
Novel glp-1 receptor modulators
|
|
WO2013182217A1
(en)
*
|
2012-04-27 |
2013-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
WO2013170636A1
(zh)
|
2012-05-18 |
2013-11-21 |
爱德迪安（北京）生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
|
CN109456400A
(zh)
|
2012-07-23 |
2019-03-12 |
西兰制药公司 |
胰高血糖素类似物
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
WO2014067084A1
(zh)
|
2012-10-31 |
2014-05-08 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的制备方法
|
|
CN102977204A
(zh)
*
|
2012-11-14 |
2013-03-20 |
吉林省敖腾生物科技有限责任公司 |
一种固相合成glp-1类似物的方法
|
|
SG10201705097PA
(en)
|
2012-12-21 |
2017-07-28 |
Sanofi Sa |
Functionalized exendin-4 derivatives
|
|
SG11201506888VA
(en)
|
2013-04-03 |
2015-09-29 |
Sanofi Sa |
Treatment of diabetes mellitus by long-acting formulations of insulins
|
|
CN105593225B
(zh)
|
2013-06-11 |
2019-04-16 |
赛尔基因第二国际有限公司 |
新型glp-1受体调节剂
|
|
CN103405753B
(zh)
*
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
RS57632B1
(sr)
|
2013-10-17 |
2018-11-30 |
Zealand Pharma As |
Acilovani analozi glukagona
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
JP2017503474A
(ja)
|
2013-11-06 |
2017-02-02 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
|
|
CN105849122B
(zh)
|
2013-11-06 |
2021-04-30 |
西兰制药公司 |
Gip-glp-1双重激动剂化合物及方法
|
|
CN105934257B
(zh)
|
2013-12-06 |
2020-10-09 |
韩捷 |
用于含氮和羟基的药物的生物可逆引入基团
|
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
CN107074820B
(zh)
|
2014-07-25 |
2021-05-18 |
赛尔基因第二国际有限公司 |
Glp-1受体调节剂
|
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
|
US12071516B2
(en)
|
2014-09-04 |
2024-08-27 |
Nano Precision Medical, Inc. |
Polymeric stabilizing formulations
|
|
WO2016037128A1
(en)
*
|
2014-09-04 |
2016-03-10 |
Nano Precision Medical, Inc. |
Polymeric stabilizing formulations
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
TWI705973B
(zh)
|
2014-10-29 |
2020-10-01 |
丹麥商西蘭製藥公司 |
Ｇｉｐ促效劑化合物及方法
|
|
KR102497644B1
(ko)
|
2014-12-10 |
2023-02-08 |
리셉토스 엘엘씨 |
Glp-1 수용체 조절제
|
|
MA41138B1
(fr)
|
2014-12-12 |
2023-07-31 |
Sanofi Aventis Deutschland |
Formulation à rapport fixe d'insuline glargine/lixisenatide
|
|
MX386778B
(es)
|
2015-03-09 |
2025-03-19 |
Intekrin Therapeutics Inc |
Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia.
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
PL3283507T3
(pl)
|
2015-04-16 |
2020-05-18 |
Zealand Pharma A/S |
Acylowany analog glukagonu
|
|
BR112017025000A2
(pt)
|
2015-05-22 |
2018-08-07 |
The Bot Of The Leland Stanford Junior University |
tratamento de hipoglicemia pós-bariátrica com exendina (9-39)
|
|
US10925639B2
(en)
|
2015-06-03 |
2021-02-23 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
|
CN106554403B
(zh)
|
2015-09-25 |
2021-08-31 |
博瑞生物医药（苏州）股份有限公司 |
艾塞那肽修饰物及其用途
|
|
CN109715662B
(zh)
|
2015-12-23 |
2023-07-21 |
美国安进公司 |
使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
|
|
WO2017152014A1
(en)
|
2016-03-04 |
2017-09-08 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
|
|
TWI754643B
(zh)
|
2016-05-16 |
2022-02-11 |
美商因塔希亞治療公司 |
升糖素受體選擇性多肽和彼之使用方法
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
WO2018057977A1
(en)
|
2016-09-23 |
2018-03-29 |
Delpor, Inc. |
Stable compositions for incretin mimetic compounds
|
|
CN107952064B
(zh)
*
|
2016-10-14 |
2023-10-20 |
江苏豪森药业集团有限公司 |
含有聚乙二醇洛塞那肽的药物制剂及其制备方法
|
|
DK3541366T3
(da)
*
|
2016-11-21 |
2025-03-03 |
Amylyx Pharmaceuticals Inc |
Bufferformuleringer af exendin (9-39)
|
|
US11285180B2
(en)
|
2016-12-06 |
2022-03-29 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
|
|
EP3551651B1
(en)
|
2016-12-09 |
2024-03-06 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018129058A1
(en)
|
2017-01-03 |
2018-07-12 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
|
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
|
CA3058806A1
(en)
|
2017-04-03 |
2018-10-11 |
Coherus Biosciences Inc. |
Ppar.gamma. agonist for treatment of progressive supranuclear palsy
|
|
WO2018237097A1
(en)
|
2017-06-20 |
2018-12-27 |
Amgen Inc. |
METHOD OF TREATING OR REDUCING METABOLIC DISORDERS USING GASTRIC INHIBITING PEPTIDE RECEPTOR BINDING PROTEINS (GIPR) IN ASSOCIATION WITH GLP-1 AGONISTS
|
|
EP3642238A1
(en)
|
2017-06-21 |
2020-04-29 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
|
|
HRP20240485T1
(hr)
|
2017-08-24 |
2024-07-05 |
Novo Nordisk A/S |
Pripravci glp-1 i njihova upotreba
|
|
RU2666148C1
(ru)
*
|
2017-10-05 |
2018-09-06 |
Общество с ограниченной ответственностью "Новые Антибиотики" |
Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
|
|
WO2020185533A1
(en)
|
2019-03-08 |
2020-09-17 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|
|
AU2020234718A1
(en)
|
2019-03-13 |
2023-05-18 |
Tearsolutions, Inc. |
Compositions and methods for promoting islet viability and enhancing insulin secretion
|
|
CN110151980B
(zh)
*
|
2019-06-30 |
2022-12-09 |
中国药科大学 |
Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
|
|
MX2022009844A
(es)
|
2020-02-18 |
2022-09-05 |
Novo Nordisk As |
Composiciones y usos del peptido similar al glucagon-1 (glp-1).
|
|
WO2022157747A2
(en)
|
2021-01-25 |
2022-07-28 |
Mylan Ireland Limited |
Pharmaceutical peptide compositions and methods of preparation thereof
|
|
CN114028537B
(zh)
*
|
2021-11-27 |
2024-03-29 |
上海万锦医药科技有限公司 |
一种含有svhrsp蝎毒肽的药物组合物及其制备方法
|
|
WO2024123812A1
(en)
|
2022-12-05 |
2024-06-13 |
Shattuck Labs, Inc. |
Fusion proteins for the treatment of cardiometabolic diseases
|